脑心通胶囊辅助治疗对颅内动脉粥样硬化性狭窄患者血小板膜糖蛋白及血小板参数的影响

摘要
图/表
参考文献
相关文章 (0)

全文: PDF (730 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的：观察脑心通辅助治疗对颅内动脉粥样硬化性狭窄患者血小板膜糖蛋白和血小板参数的影响。方法: 122例颅内动脉粥样硬化性狭窄患者随机分成2组:脑心通组(n=64)和基础治疗组(n=58);脑心通组每日服用拜阿司匹林、立普妥和步长脑心通;基础治疗组每日服用拜阿司匹林和立普妥,服药6个月,比较两组患者治疗前后血小板膜糖蛋白PAC-1和CD62P表达、血小板计数(PLT)、平均血小板体积(MPV)、血小板分布宽度(PDW)和大血小板比率(P-LCR)的改变。结果: 与治疗前相比,治疗后两组血小板膜糖蛋白PAC-1、CD62P表达,MPV、PDW和P-LCR均显著降低,PLT计数均显著增高,其中脑心通组P均<0.01,基础治疗组P均<0.05。两组治疗后各指标比较，差异均有统计学意义（P<0.05）。结论: 脑心通辅助治疗可进一步抑制血小板活化，抗血小板聚集,延缓颅内动脉粥样硬化性狭窄的发展。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：动脉粥样硬化性狭窄, 血小板膜糖蛋白, 血小板参数, 脑心通

Abstract：Objective: To observe the effect of naoxintong capsule add-on therapy on platelet membrane glycoprotein and parameters in patients with intracranial atherosclerotic stenosis. Methods: One hundred and twenty-two patients with intracranial atherosclerotic stenosis were randomly divided into 2 groups: naoxintong capsule(n=64) and conventional western medicine(n=58). The conventional western medicine aspirin and lipitor were given to the two groups, while naoxintong capsule was additionally given to the former group. The therapeutic course for all were 6 months. The expression of platelet membrane glycoprotein PAC-1 and CD62P, platelet count(PLT), mean platelet volume(MPV), platelet distribution width(PDW) and platelet large cell ratio(P-LCR) were detected in 2 groups before and after treatment. Results: Compared with before treatment, the expression of platelet membrane glycoprotein PAC-1 and CD62P, MPV, PDW and P-LCR were significantly lower, the PLT count were significantly higher in both two groups. The differences of platelet membrane glycoprotein expression and parameters after naoxintong capsule add on therapy were more significant than conventional western therapy only. Conclusion: Naoxintong capsule add-on therapy could further inhibit the activation and aggregation of platelet, assist conventional western therapy in postponing the development of intracranial atherosclerotic stenosis.

收稿日期: 2012-10-26

通讯作者: 俞龙，副主任医师，E-mail：yzchendr@gmail.com

作者简介: 张娴娴（1987—），女，硕士研究生

引用本文:

张娴娴, 肖璐, 陈兰兰, 朱艳, 吴健, 陈应柱, 俞龙, 李军. 脑心通胶囊辅助治疗对颅内动脉粥样硬化性狭窄患者血小板膜糖蛋白及血小板参数的影响[J]. 江苏大学学报:医学版, 2013, 23(1): 65-68. ZHANG Xian-xian, XIAO Lu, CHEN Lan-lan, ZHU Yan, WU Jian, CHEN Ying-zhu, YU Long, LI Jun.
Effect of naoxintong capsule addon therapy on platelet membrane glycoprotein and parameters in patients with intracranial atherosclerotic stenosis. Journal of Jiangsu University(Medicine Edition), 2013, 23(1): 65-68.

链接本文:

http://zzs.ujs.edu.cn/xbyxb/CN/ 或 http://zzs.ujs.edu.cn/xbyxb/CN/Y2013/V23/I1/65

[1] Kasner SE, Chimowitz MI, Lynn MJ, et al. Predictors of ischemic stroke in the territory of a symptomatic intracranial arterial stenosis［J］. Circulation, 2006,113(4): 555-563.

［2］ Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association／American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline［J］. Stroke, 2006, 37(2): 577-617.

［3］高山,黄家星,黄一宁,等. 颅内大动脉狭窄的检查方法和流行病学调查［J］. 中国医学科学院学报, 2003, 25(1): 96-100.

［4］ Gawaz M, Langer H, May AE. Platelets in inflammation and atherogenesis［J］. J Clin Invest, 2005, 115(12):3378-3384.

［5］ Wang WY, Wu YC, Wu CC. Prevention of platelet glycoprotein Ⅱb／Ⅲa activation by 3,4-methylenedioxy-beta-nitrostyrene, a novel tyrosine kinase inhibitor［J］. Mol Pharmacol, 2006, 70(4):1380-1389.

［6］ Danielyan K, Ding BS, Gottstein C, et al. Delivery of anti-platelet-endothelial cell adhesion molecule singlechain variable fragmenturokinase fusion protein to the cerebral vasculature lyses arterial clots and attenuates postischemic brain edema［J］.J Pharmacol Exp Ther, 2007, 321(3): 947-952.

［7］ Lindemann S, Krmer B, Seizer P, et al. Platelets, inflammation and atherosclerosis［J］. J Thromb Haemost, 2007, 5（suppl 1）: 203-211.

［8］ Langer HF, Bigalke B, Seizer P, et al. Interaction of platelets and inflammatory endothelium in the development and progression of coronary artery disease［J］. Semin Thromb Hemost, 2010, 36(2):131-138.

［9］ Ay C, Jungbauer LV, Kaider A, et al. P-selectin gene haplotypes modulate soluble P-selectin concentrations and contribute to the risk of venous thromboembolism［J］. Thromb Haemost, 2008, 99(5):899-904.

［10］ SiegelAxel D, Daub K, Seizer P, et al. Platelet lipoprotein interplay: trigger of foam cell formation and driver of atherosclerosis［J］. Cardiovasc Res, 2008, 78(1):8-17.

［11］ Marwali MR, Hu CP, Mohandas B, et al. Modulation of ADP-induced platelet activation by aspirin and pravastatin: role of letin-like oxidized low-density lipoprotein receptor-1, nitric oxide, oxidative stress, and insideout integrin signaling［J］. J Pharmacol Exp Ther, 2007, 322(3): 1324-1332.

［12］ Benner JS, Pollack MF, Smith TW,et al. Association between short-term effectiveness of statins and long term adherence to lipid-lowering therapy［J］. Am J Health Syst Pharm, 2005, 62(14):1468-1475.

［13］ Puccetti L, Sawamura T, Pasgui AL, et al. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients［J］. Eur J Clin Invest, 2005, 35(1): 47-51.